The Chemours Company provides performance chemicals in North America, the Asia Pacific, Europe, the Middle East, Africa, and Latin America. More Details
Fair value with mediocre balance sheet.
Share Price & News
How has Chemours's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: CC is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 6% a week.
Volatility Over Time: CC's weekly volatility (6%) has been stable over the past year.
7 Day Return
1 Year Return
Return vs Industry: CC exceeded the US Chemicals industry which returned 35.3% over the past year.
Return vs Market: CC exceeded the US Market which returned 35.9% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is Chemours's share price compared to the market and industry in the last 5 years?
Simply Wall St News
2 weeks ago | Simply Wall StHere's Why Chemours (NYSE:CC) Has A Meaningful Debt Burden
1 month ago | Simply Wall StChemours (NYSE:CC) Has Rewarded Shareholders With An Exceptional 374% Total Return On Their Investment
2 months ago | Simply Wall StHere's What The Chemours Company's (NYSE:CC) Shareholder Ownership Structure Looks Like
Is Chemours undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: CC ($33.25) is trading below our estimate of fair value ($110.84)
Significantly Below Fair Value: CC is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: CC is good value based on its PE Ratio (21.5x) compared to the US Chemicals industry average (25x).
PE vs Market: CC is poor value based on its PE Ratio (21.5x) compared to the US market (18.1x).
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate CC's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: CC is overvalued based on its PB Ratio (6.1x) compared to the US Chemicals industry average (3x).
How is Chemours forecast to perform in the next 1 to 3 years based on estimates from 9 analysts?
Forecasted annual revenue growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: Insufficient data to determine if CC's forecast earnings growth is above the savings rate (2%).
Earnings vs Market: Insufficient data to determine if CC's earnings are forecast to grow faster than the US market
High Growth Earnings: Insufficient data to determine if earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: CC's revenue (5.3% per year) is forecast to grow slower than the US market (9.2% per year).
High Growth Revenue: CC's revenue (5.3% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: CC's Return on Equity is forecast to be very high in 3 years time (47%).
How has Chemours performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: CC has a large one-off loss of $92.0M impacting its June 30 2021 financial results.
Growing Profit Margin: CC became profitable in the past.
Past Earnings Growth Analysis
Earnings Trend: CC has become profitable over the past 5 years, growing earnings by -7.4% per year.
Accelerating Growth: CC has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: CC has become profitable in the last year, making it difficult to compare its past year earnings growth to the Chemicals industry (28.2%).
Return on Equity
High ROE: Whilst CC's Return on Equity (28.44%) is high, this metric is skewed due to their high level of debt.
How is Chemours's financial position?
Financial Position Analysis
Short Term Liabilities: CC's short term assets ($3.0B) exceed its short term liabilities ($1.7B).
Long Term Liabilities: CC's short term assets ($3.0B) do not cover its long term liabilities ($4.9B).
Debt to Equity History and Analysis
Debt Level: CC's debt to equity ratio (433.8%) is considered high.
Reducing Debt: CC's debt to equity ratio has reduced from 2252% to 433.8% over the past 5 years.
Debt Coverage: CC's debt is well covered by operating cash flow (24.3%).
Interest Coverage: CC's interest payments on its debt are not well covered by EBIT (2.3x coverage).
What is Chemours's current dividend yield, its reliability and sustainability?
Current Dividend Yield
Upcoming Dividend Payment
Dividend Yield vs Market
Notable Dividend: CC's dividend (3.01%) is higher than the bottom 25% of dividend payers in the US market (1.31%).
High Dividend: CC's dividend (3.01%) is low compared to the top 25% of dividend payers in the US market (3.55%).
Stability and Growth of Payments
Stable Dividend: Whilst dividend payments have been stable, CC has been paying a dividend for less than 10 years.
Growing Dividend: CC's dividend payments have increased, but the company has only paid a dividend for 6 years.
Current Payout to Shareholders
Dividend Coverage: With its reasonable payout ratio (64.6%), CC's dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: CC's dividends in 3 years are forecast to be well covered by earnings (24.7% payout ratio).
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Mark Newman (58 yo)
Mr. Mark E. Newman serves as Chief Executive Officer, President and Director at The Chemours Company since July 1, 2021. He joined Chemours in 2014. Mr. Newman served as the Chief Operating Officer of The ...
CEO Compensation Analysis
Compensation vs Market: Mark's total compensation ($USD3.00M) is below average for companies of similar size in the US market ($USD6.51M).
Compensation vs Earnings: Mark's compensation has been consistent with company performance over the past year.
Experienced Management: CC's management team is not considered experienced ( 0.5 years average tenure), which suggests a new team.
Experienced Board: CC's board of directors are considered experienced (6 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
The Chemours Company's company bio, employee growth, exchange listings and data sources
- Name: The Chemours Company
- Ticker: CC
- Exchange: NYSE
- Founded: 2014
- Industry: Diversified Chemicals
- Sector: Materials
- Market Cap: US$5.492b
- Shares outstanding: 165.16m
- Website: https://www.chemours.com
Number of Employees
- The Chemours Company
- 1007 Market Street
- P.O. Box 2047
- United States
The Chemours Company provides performance chemicals in North America, the Asia Pacific, Europe, the Middle East, Africa, and Latin America. It operates through four segments: Titanium Technologies, Thermal...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/08/01 22:36|
|End of Day Share Price||2021/07/30 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.